Skip to content
lifestyle.fairytaleinkbooks.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
OKYO Pharma LTD
OKYO Pharma Announces Chief Development Officer and Director Acquires Shares
March 19, 2026
OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain
March 18, 2026
OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress
February 23, 2026
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares
February 14, 2026
OKYO Pharma Announces Public Offering of Ordinary Shares
February 14, 2026
OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners
February 13, 2026
OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer
February 12, 2026
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting
January 30, 2026
OKYO Pharma Announces Successful Type C Meeting with the FDA
January 28, 2026
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain
January 23, 2026
←
Previous Page
1
2